Unicycive Therapeutics, Inc. (UNCY) — research page

US · us-cm-kg/NASDAQ/UNCY · as of 2026-11-08

Identity and listing

The issuer is Unicycive Therapeutics, Inc., listed on NASDAQ under ticker UNCY. Its ISIN is US90466Y2028. Its LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-DE). Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States, Delaware. Its listing status is listed, not halted.

The disclosure read

The record holds 56 filings in the twelve months to 2026-11-08, across 30 filing days. The filings comprise 4 agm_egm, 4 corporate_news, 2 director_change, 16 directors_dealings, 2 prospectus, 20 regulatory_filing and 8 results. The median gap between filing days is 6 days. The latest filing is dated 2026-10-29 and is of type directors_dealings, 10 days before the record date. The exchange median for NASDAQ is 52 filings, a cadence gap of 6.0 days and a latency of 5.0 days across 4359 issuers. The sector median for 2834 Pharmaceutical Preparations is 63.0 filings, a cadence gap of 6.0 days and a latency of 4.0 days across 526 issuers.

window 2025-11-08 to 2026-11-08 · the node's disclosure lines, as get_filings serves them

Auditor

The auditor of record is GRASSI & CO., CPAs, P.C., located in Jericho, New York. The record holds no auditor changes.

Events and halts

The record holds no listing, delisting or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record (the exchanges' tier transfers are not EDGAR filings). The halt flag reads listed, not halted.

Orderability

The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.

rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability

Coverage

The issuer's own investor-relations page names 10 research houses: B. Riley, Brookline Capital Markets, Guggenheim Securities, H.C. Wainwright, Lucid Capital Markets, Maxim Group, Noble Life Science Partners, Piper Sandler, The Benchmark Company, LLC, and WestPark Capital.

Open research

No openly published research notes were found on the record.

Licensed

Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.

As-of depth

The sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. The market's vintage is sealed.

Sources

9 source pages are named on this page; every value above carries its own source page and read date in the numbers.

10.1

https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)

10.2

https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)

10.3

https://data.sec.gov/submissions/CIK0001766140.json (identity.jurisdiction)

10.4

https://mcp.us-cm-kg.ai/events/NASDAQ/UNCY (the disclosure lines)

10.5

https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)

10.6

https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm (the auditor)

10.7

https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)

10.8

https://ir.unicycive.com/financial-stock-info/analyst-coverage (coverage)

10.9

https://mcp.us-cm-kg.ai/record/NASDAQ/UNCY (the record)

Read it by agent

The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"US90466Y2028"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:77ca781f9f4b3b88.